SILICOSIS

DEFINITION

OCCUPATIONS AND INDUSTRIES AT RISK

PATHOGENESIS

1. Particle uptake - Alveolar macrophages engulf silica particles; the unique surface physico-chemical properties of crystalline silica make it toxic to macrophages
2. Macrophage injury - Silica induces lysosomal membrane disruption, releasing lysosomal enzymes and reactive oxygen species, leading to macrophage death
3. Inflammatory cascade - Dead macrophages release silica particles which are re-engulfed by new macrophages, perpetuating an unrelenting cycle. Macrophages release pro-inflammatory and pro-fibrotic mediators (IL-1, TNF-α, TGF-β)
4. Fibrogenesis - TGF-β drives fibroblast proliferation and collagen deposition, producing the characteristic whorled hyalinized collagen nodule
5. Cumulative exposure - Tissue reaction severity is determined by the quantity and duration of accumulated dust and the surface physico-chemical properties of the particles

CLINICOPATHOLOGICAL TYPES

1. Chronic (Simple) Silicosis

• Most common form; follows exposure measured in decades (typically >10 years at moderate dust levels)
• Pathological hallmark: silicotic nodule - well-circumscribed, with:
  • Central zone of acellular hyalinized collagen with a whorled ("onion-skin") appearance
  • Peripheral zone of dust-laden macrophages
• Nodules appear first in hilar lymph nodes, then lung parenchyma
• Distribution: bilateral, predominantly upper lung zones
• May progress to complicated silicosis (PMF) with nodule coalescence

2. Accelerated Silicosis

• Follows heavier exposure over 5-10 years
• Similar pathology to chronic silicosis but more rapid progression
• Greater risk of complications (TB, autoimmune disease)

3. Acute Silicosis (Silicoproteinosis)

• Follows massive, intense, short-term exposure (weeks to 5 years) to very high concentrations of fine-particle silica
• Pathologically resembles pulmonary alveolar proteinosis - alveoli are filled with lipoproteinaceous material (PAS-positive)
• Clinically severe: rapidly progressive dyspnea, hypoxemia, respiratory failure, death
• Must be distinguished from chronic/accelerated forms clinically

PATHOLOGY

• Nodules grow and coalesce to form lesions >1 cm (often much larger)
• Predominantly involves upper lobes
• Causes substantial scarring and volume loss
• May cavitate (raises suspicion of superimposed tuberculosis or fungal infection)
• Silicotic nodules may calcify peripherally - "eggshell calcification" of hilar/mediastinal nodes (pathognomonic)

CLINICAL FEATURES

• Chronic silicosis: often asymptomatic for years; progressive dyspnea on exertion is the dominant symptom; cough (with or without sputum)
• Accelerated silicosis: more rapid progression of dyspnea
• Acute silicosis: severe dyspnea, cyanosis, weight loss, and respiratory failure
• Complicated silicosis (PMF): significant dyspnea, cough with black sputum (melanoptysis)

• May be unremarkable in simple silicosis
• Advanced disease: reduced breath sounds, fine crackles, signs of cor pulmonale (right heart failure), clubbing is uncommon

RADIOGRAPHIC FEATURES

• Small rounded opacities (nodules), predominantly in upper and mid zones, bilaterally
• ILO profusion scores used to quantify disease
• PMF: large opacities (>1 cm) in upper zones, which migrate toward the hilum as they enlarge
• Eggshell calcification of hilar/mediastinal lymph nodes (pathognomonic but not always present)

• Centrilobular and subpleural nodules, upper lobe predominance
• Branching pattern of nodules (pseudoplaque)
• Ground-glass opacity in acute silicosis
• PMF: large irregular masses with background nodules

PULMONARY FUNCTION TESTS

• May be normal in simple silicosis
• Restrictive pattern with reduced TLC, FVC (most classic)
• Obstructive pattern - actually the more common finding in many studies; silica exposure causes clinically important airflow limitation independent of radiographic abnormality (related to silica-induced emphysema)
• Mixed pattern in advanced disease
• DLCO (diffusing capacity) may be reduced, even without spirometric abnormality
• Advanced disease: severe restriction, hypoxemia, cor pulmonale
• In acute silicosis: rapid progression to gas exchange failure and respiratory failure
• 6-minute walk distance (6MWD) is a prognostic factor for hospitalization and mortality

COMPLICATIONS

1. Tuberculosis (Silicotuberculosis) - Most important and serious complication
   • Silica dust impairs macrophage killing of mycobacteria
   • Risk of TB is substantially elevated (6-30x that of general population)
   • PPD induration >10 mm is considered positive in silica-exposed workers
   • Any cavitation in a silicosis patient should raise suspicion for TB
   • Active TB should be treated with standard regimens; rifampicin must be included
   • In miners with significant silica exposure, treatment should be more prolonged given risk of recurrence
2. Lung Cancer - In 1997, IARC reclassified crystalline silica as a Group I carcinogen ("sufficient evidence" in humans). Risk is especially elevated in those with silicosis itself. The relationship between silicosis/fibrosis and cancer continues to be studied.
3. Connective Tissue Diseases - Strong association with:
   • Scleroderma (systemic sclerosis) - the "Erasmus syndrome" (scleroderma + silicosis in miners)
   • Rheumatoid arthritis (Caplan's syndrome when rheumatoid nodules develop in silicotic lungs)
   • SLE and ANCA-associated vasculitis
   • Mechanisms likely involve silica-induced immune dysregulation
4. Renal Disease - Silica exposure associated with ~5.1% excess risk of end-stage renal disease (ESRD) and excess risk of ANCA-associated glomerulonephritis
5. Cardiovascular disease - Right heart failure (cor pulmonale) from pulmonary hypertension in advanced disease
6. Infections - In acute silicosis: Nocardia and fungal infections (in addition to TB)

DIAGNOSIS

1. Occupational exposure history - sufficient duration and intensity of crystalline silica exposure (most important - job titles alone are insufficient; a complete exposure history including military service, summer jobs, and avocations is essential)
2. Characteristic chest imaging - bilateral upper-zone nodularity, with or without PMF or eggshell calcification
3. Compatible clinical picture

• Radiological features are atypical
• Concern for neoplasm or tuberculosis exists
• The exposure history is uncertain

MANAGEMENT

A. Medical Treatment

• Bronchodilators - for symptomatic airflow obstruction; systemic/inhaled corticosteroids if reversible component is documented
• Oxygen therapy - indicated when PaO2 ≤55 mmHg; improves exercise tolerance, reduces dyspnea, prevents arrhythmias and polycythemia
• Vaccination - influenza and pneumococcal vaccines are recommended
• Whole lung lavage - has been used to remove accumulated dust and inflammatory mediators; evidence for routine use is insufficient but may be considered in acute/accelerated silicosis
• Antifibrotics (experimental) - Nintedanib and Pirfenidone are being investigated in trials of silicosis/pneumoconiosis given overlap with IPF pathways (TGF-β, fibroblast proliferation); NIPS trial ongoing

B. Treatment of Complications

• TB/mycobacterial disease: standard regimens including rifampicin; prolonged treatment in heavy silica-exposed miners; long-term follow-up for recurrence
• Connective tissue diseases: immunosuppressive therapy as indicated
• Cor pulmonale: standard heart failure management, oxygen

C. Lung Transplantation

• Option for end-stage disease with severe functional limitation

D. Secondary Prevention

• Removal from further silica exposure is essential
• Smoking cessation is imperative

PREVENTION

1. Engineering controls - wet drilling, enclosed cabs, local exhaust ventilation, substitution of non-siliceous abrasives for sandblasting
2. Administrative controls - job rotation, limiting time in high-exposure areas
3. Personal protective equipment - appropriate respirators (not dust masks)
4. Medical surveillance - periodic chest radiographs (ILO classification) and spirometry for exposed workers
5. Regulatory controls - OSHA permissible exposure limits (PEL) for respirable silica (0.05 mg/m³)
6. No preventive drug therapy has proven effective

PROGNOSIS

• Chronic simple silicosis: may remain stable or slowly progress; disease can progress even after cessation of exposure
• PMF: progressive; causes significant disability and reduced lifespan
• Acute silicosis: rapidly fatal; median survival from diagnosis is 2-3 years
• Major causes of death: respiratory failure, cor pulmonale, TB, lung cancer
• Disease may progress or initially develop after cessation of exposure due to incomplete dust clearance - former silica workers should receive regular radiographic and physiologic follow-up

SUMMARY TABLE

• Silica = crystalline SiO2 (quartz most common); amorphous silica is non-toxic
• Pathological hallmark = silicotic nodule with whorled hyalinized collagen + peripheral dust-laden macrophages; upper lobe distribution
• Eggshell calcification of hilar nodes = pathognomonic
• Most important complication = silicotuberculosis; IARC Group I carcinogen
• No specific treatment; disease may progress after stopping exposure
• Lung biopsy rarely needed; diagnosis by exposure history + imaging